PT2710039T - Composições anti-cgrp e a sua utilização - Google Patents

Composições anti-cgrp e a sua utilização

Info

Publication number
PT2710039T
PT2710039T PT12789693T PT12789693T PT2710039T PT 2710039 T PT2710039 T PT 2710039T PT 12789693 T PT12789693 T PT 12789693T PT 12789693 T PT12789693 T PT 12789693T PT 2710039 T PT2710039 T PT 2710039T
Authority
PT
Portugal
Prior art keywords
cgrp compositions
cgrp
compositions
Prior art date
Application number
PT12789693T
Other languages
English (en)
Inventor
Fernando Garcia-Martinez Leon
Latham John
Dianne Mcneill Patricia
Olson Katie
Kovacevich Brian
H Dutzar Benjamin
J Billgren Jens
M Mitchell Danielle
M Janson Nicole
Loomis Maria-Cristina
Original Assignee
Alderbio Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47175055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2710039(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alderbio Holdings Llc filed Critical Alderbio Holdings Llc
Publication of PT2710039T publication Critical patent/PT2710039T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
PT12789693T 2011-05-20 2012-05-21 Composições anti-cgrp e a sua utilização PT2710039T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161488660P 2011-05-20 2011-05-20

Publications (1)

Publication Number Publication Date
PT2710039T true PT2710039T (pt) 2019-04-23

Family

ID=47175055

Family Applications (3)

Application Number Title Priority Date Filing Date
PT12789693T PT2710039T (pt) 2011-05-20 2012-05-21 Composições anti-cgrp e a sua utilização
PT182035188T PT3495392T (pt) 2011-05-20 2012-05-21 Composições anti-cgrp e a sua utilização
PT192153039T PT3662932T (pt) 2011-05-20 2012-05-21 Composições anti-cgrp e a sua utilização

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT182035188T PT3495392T (pt) 2011-05-20 2012-05-21 Composições anti-cgrp e a sua utilização
PT192153039T PT3662932T (pt) 2011-05-20 2012-05-21 Composições anti-cgrp e a sua utilização

Country Status (35)

Country Link
US (9) US9745373B2 (pt)
EP (5) EP4115905A1 (pt)
JP (3) JP6282584B2 (pt)
KR (1) KR102128627B1 (pt)
CN (5) CN107602700B (pt)
AP (1) AP2013007259A0 (pt)
AR (3) AR086516A1 (pt)
AU (3) AU2012258966C1 (pt)
BR (2) BR122022012930B1 (pt)
CA (3) CA3079978A1 (pt)
CL (3) CL2013003336A1 (pt)
CO (1) CO6870005A2 (pt)
CY (2) CY1124209T1 (pt)
DK (3) DK2710039T3 (pt)
EA (3) EA201891284A1 (pt)
ES (3) ES2873837T3 (pt)
FR (1) FR22C1032I2 (pt)
HR (3) HRP20190640T1 (pt)
HU (4) HUE055505T2 (pt)
IL (4) IL229431B (pt)
LT (4) LT3662932T (pt)
MX (3) MX370749B (pt)
NL (1) NL301181I2 (pt)
NZ (1) NZ733060A (pt)
PE (2) PE20141787A1 (pt)
PH (1) PH12018500521A1 (pt)
PL (3) PL2710039T3 (pt)
PT (3) PT2710039T (pt)
RS (3) RS58621B1 (pt)
SG (2) SG10201604040PA (pt)
SI (3) SI2710039T1 (pt)
TR (1) TR201904088T4 (pt)
TW (4) TWI685505B (pt)
WO (1) WO2012162243A2 (pt)
ZA (1) ZA201308637B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2008004467A0 (en) 2005-11-14 2008-06-30 Rinat Neurosciene Corp Antagonist antibodies directed against calcitonin generelated peptide anf methods using same
BRPI0907135B8 (pt) 2008-03-04 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
DK2710039T3 (en) * 2011-05-20 2019-04-01 Alderbio Holdings Llc ANTI-CGRP COMPOSITIONS AND APPLICATION THEREOF
EP2709662B1 (en) 2011-05-20 2019-07-31 AlderBio Holdings LLC Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
SG194973A1 (en) 2011-05-20 2013-12-30 Alderbio Holdings Llc Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
EP2970865B1 (en) 2013-03-15 2020-09-02 Alder Biopharmaceuticals, Inc. Antibody purification and purity monitoring
CN105492026A (zh) * 2013-07-03 2016-04-13 奥尔德生物制药公司 使用抗cgrp抗体的葡萄糖代谢的调节
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX2016012188A (es) 2014-03-21 2017-04-27 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
TWI721975B (zh) * 2015-04-16 2021-03-21 美商艾爾德生物製藥股份有限公司 抗ｐａｃａｐ抗體及其用途
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
WO2017051385A1 (en) * 2015-09-24 2017-03-30 Teva Pharmaceuticals International Gmbh Preventing, treating, and reducing (persistent) post-traumatic headache
TW201725212A (zh) * 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
JP2019501152A (ja) * 2016-01-28 2019-01-17 イーライ リリー アンド カンパニー Ｃｇｒｐ抗体及びその使用
US11492386B2 (en) 2016-02-01 2022-11-08 Eli Lilly And Company Parathyroid hormone-anti-RANKL antibody fusion compounds
AU2017250807A1 (en) 2016-04-15 2018-10-25 H. Lundbeck A/S. Anti-PACAP antibodies and uses thereof
JP2019529463A (ja) 2016-09-23 2019-10-17 テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー 群発頭痛の治療方法
JP6937368B2 (ja) 2016-09-23 2021-09-22 テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー 難治性片頭痛の治療方法
WO2018160896A1 (en) 2017-03-02 2018-09-07 Beth Israel Deaconess Medical Center Selecting headache patients responsive to antibodies directed against calcitonin gene related peptide
JP7339262B2 (ja) 2018-01-12 2023-09-05 アムジェン インコーポレイテッド Ｐａｃ１抗体及びその使用
US11274158B2 (en) * 2018-01-30 2022-03-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
WO2019165326A1 (en) * 2018-02-23 2019-08-29 REMD Biotherapeutics, Inc Calcitonin gene-related peptide (cgrp) antagonist antibodies
WO2019231800A1 (en) * 2018-05-31 2019-12-05 Eli Lilly And Company Anti-cgrp antibodies for treating menstrual-related migraines
US10899826B1 (en) * 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
EP3674418A1 (en) * 2018-12-26 2020-07-01 Life Length S.L. Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases
CR20210373A (es) 2019-01-08 2021-08-19 H Lundbeck As Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
CA3123292A1 (en) * 2019-01-08 2020-07-16 Roger K. Cady Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
BR112021016996A8 (pt) * 2019-02-28 2022-11-22 Dandi Bioscience Inc Polipeptídeo com atividade antibacteriana, composição para prevenir ou tratar sepsis compreendendo a mesma e composição antibacteriana
EA202192865A1 (ru) * 2019-05-02 2022-02-14 Х. Лундбекк А/С Лечение головной боли с использованием антител к cgrp
WO2020239014A1 (zh) * 2019-05-30 2020-12-03 山东博安生物技术有限公司 抗cgrp抗体及其应用
KR20210124867A (ko) 2020-04-06 2021-10-15 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び／又は発生の低減
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
CA3229059A1 (en) 2021-08-27 2023-03-02 H. Lundbeck A/S Treatment of cluster headache using anti-cgrp antibodies
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
CN117586390A (zh) * 2022-08-11 2024-02-23 上海君实生物医药科技股份有限公司 抗cgrp抗体及用途

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3662333A (en) 1970-09-08 1972-05-09 Bendix Corp Hydraulic accumulator charge detector and indicating system
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5123197A (ja) 1974-08-21 1976-02-24 Hitachi Ltd Purosesugasukuromatogurafuno ondoseigyohoshiki
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE134631T1 (de) * 1983-06-15 1985-12-05 Roger Kingdom Craig Peptide, pharmazeutische zusammensetzungen, gene, vektoren, wirtorganismen, verfahren zu deren herstellung und diagnostische reagenzien.
JPS62129297A (ja) 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5266561A (en) 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5364841A (en) 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
FR2669336B1 (fr) 1990-11-20 1993-01-22 Adir Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE4227454C1 (de) * 1992-08-19 1994-02-03 Henning Berlin Gmbh Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
WO1994021293A1 (en) 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5475995A (en) 1994-05-16 1995-12-19 Livingston; George G. Truck spare tire locking rod
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
IL114909A (en) 1994-08-12 1999-10-28 Immunomedics Inc Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
JPH10504457A (ja) 1994-08-16 1998-05-06 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド カルシトニンレセプター
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
EP0851759A4 (en) 1995-09-05 2000-12-06 Smithkline Beecham Corp COMPOUNDS AND RELATED METHODS
US5710024A (en) * 1996-07-23 1998-01-20 Smithkline Beecham Corporation Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
JP2002511836A (ja) 1996-09-09 2002-04-16 スミスクライン・ビーチャム・コーポレイション 化合物および方法
SK285631B6 (sk) 1996-09-10 2007-05-03 Dr. Karl Thomae Gmbh Modifikované aminokyseliny, farmaceutický prostriedok s ich obsahom a ich použitie
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
WO1998056779A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
WO2000018764A1 (en) 1998-09-30 2000-04-06 Merck Sharp & Dohme Limited Benzimidazolinyl piperidines as cgrp ligands
US20010036647A1 (en) 1998-10-22 2001-11-01 Prabhakara V. Choudary Functionally assembled antigen-specific intact recombinant antibody and a method for production thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1031350A1 (en) 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
UA77152C2 (en) 1999-09-25 2006-11-15 Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma
DK1259547T3 (da) 2000-03-01 2012-10-15 Medimmune Inc Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
US20020162125A1 (en) 2001-03-06 2002-10-31 Anne-Marie Salmon Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal
US20030181462A1 (en) 2001-08-17 2003-09-25 Boehringer Ingelheim Pharma Kg Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
CA2471833A1 (en) 2001-11-26 2003-06-05 Protemix Corporation Limited Methods of compositions for normalizing lipid levels in mammalian tissues
EP1527100B1 (en) 2002-03-29 2009-07-01 Schering Corporation Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
US7879991B2 (en) 2002-05-06 2011-02-01 Noxxon Pharma Ag CGRP binding nucleic acids
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
KR20050008790A (ko) 2002-06-05 2005-01-21 브리스톨-마이어스 스큅 컴퍼니 칼시토닌 유전자 관련 펩티드 수용체 길항제
JP2006512895A (ja) 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
DE60326370D1 (de) 2002-08-12 2009-04-09 Actavis Group Hf Verwendung von cgrp-antagonisten-verbindungen zur behandlung von psoriasis
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2004050683A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
EP1575517B1 (en) 2002-12-24 2012-04-11 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
CA2519515A1 (en) 2003-03-14 2004-10-14 Merck & Co., Inc. Benodiazepine spirohydantoin cgrp receptor antagonists
EP1613368B1 (en) 2003-03-14 2011-11-30 Merck Sharp & Dohme Corp. Carboxamide spirohydantoin cgrp receptor antagonists
WO2004083187A1 (en) 2003-03-14 2004-09-30 Merck & Co. Inc. Monocyclic anilide spirohydantoin cgrp receptor antagonists
AU2004222383B2 (en) 2003-03-14 2009-10-01 Merck Sharp & Dohme Corp. Bicyclic anilide spirohydantoin CGRP receptor antagonists
ATE516803T1 (de) 2003-03-14 2011-08-15 Merck Sharp & Dohme Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
ATE466860T1 (de) 2003-04-15 2010-05-15 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
CN100418948C (zh) 2003-07-15 2008-09-17 麦克公司 羟基吡啶cgrp受体抗拮抗剂
ES2393555T3 (es) * 2003-10-22 2012-12-26 Keck Graduate Institute Métodos para la síntesis de polipéptidos hetero-multiméricos en levaduras usando una estrategia de apareamiento haploide.
WO2005041757A2 (en) 2003-10-29 2005-05-12 University Of Rochester Detection of neuropeptides associated with pelvic pain disorders and uses thereof
CA2552757A1 (en) 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods of using cgrp for cardiovascular and renal indications
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018794A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
TWI432196B (zh) 2005-01-18 2014-04-01 Euro Celtique Sa 內臟痛的治療
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
CA2619856A1 (en) 2005-08-25 2007-03-01 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US20070108378A1 (en) 2005-11-14 2007-05-17 Toru Terabayashi High pressure optical cell for a downhole optical fluid analyzer
AP2008004467A0 (en) 2005-11-14 2008-06-30 Rinat Neurosciene Corp Antagonist antibodies directed against calcitonin generelated peptide anf methods using same
EP1951251B1 (en) 2005-11-18 2010-12-29 Merck Sharp & Dohme Corp. Spirohydantoin aryl cgrp receptor antagonists
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
US9074352B2 (en) 2006-03-27 2015-07-07 John R. Ramun Universal control scheme for mobile hydraulic equipment and method for achieving the same
EP2021463B1 (en) 2006-05-19 2016-11-23 Alder Biopharmaceuticals, Inc. Culture method for obtaining a clonal population of antigen-specific b cells
WO2007141285A1 (en) 2006-06-08 2007-12-13 Boehringer Ingelheim International Gmbh Treatment of gastrointestinal disorders with cgrp-antagonists
CA2658573A1 (en) 2006-07-21 2008-01-24 Vertex Pharmaceuticals Incorporated Cgrp receptor antagonists
US8075902B2 (en) * 2007-01-03 2011-12-13 Michael Powell Diagnosis and treatment of cancer related to human dormancy
NZ597767A (en) 2007-05-21 2013-06-28 Bristol Myers Squibb Co Antibodies to IL-6 and use thereof
US9056905B2 (en) 2007-05-21 2015-06-16 Alderbio Holdings Llc Antibodies to TNF-α and use thereof
US20090104187A1 (en) 2007-05-21 2009-04-23 Alder Biopharmaceuticals, Inc. Novel Rabbit Antibody Humanization Methods and Humanized Rabbit Antibodies
GB0725103D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Novel compounds
DK2265288T3 (en) 2008-03-04 2016-06-06 Labrys Biologics Inc Methods for the treatment of inflammatory pain
BRPI0907135B8 (pt) * 2008-03-04 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
AU2010288194B2 (en) 2009-08-28 2013-08-29 Teva Pharmaceuticals International Gmbh Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
JO3330B1 (ar) 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
US11214610B2 (en) * 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
SG194973A1 (en) 2011-05-20 2013-12-30 Alderbio Holdings Llc Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
DK2710039T3 (en) * 2011-05-20 2019-04-01 Alderbio Holdings Llc ANTI-CGRP COMPOSITIONS AND APPLICATION THEREOF
EP2709662B1 (en) 2011-05-20 2019-07-31 AlderBio Holdings LLC Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
WO2017051385A1 (en) 2015-09-24 2017-03-30 Teva Pharmaceuticals International Gmbh Preventing, treating, and reducing (persistent) post-traumatic headache
WO2018160896A1 (en) * 2017-03-02 2018-09-07 Beth Israel Deaconess Medical Center Selecting headache patients responsive to antibodies directed against calcitonin gene related peptide
US11752099B2 (en) * 2017-03-27 2023-09-12 W. L. Gore & Associates, Inc. Injectable and biodegradable polymer formulations for controlled release of bioactive agents
WO2018236873A1 (en) * 2017-06-19 2018-12-27 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIAL INFECTION
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
CA3123292A1 (en) 2019-01-08 2020-07-16 Roger K. Cady Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
CR20210373A (es) * 2019-01-08 2021-08-19 H Lundbeck As Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp

Also Published As

Publication number Publication date
IL229431A0 (en) 2014-01-30
EA201301295A1 (ru) 2014-04-30
NZ733060A (en) 2022-08-26
CN107602700B (zh) 2021-12-17
US20180215813A1 (en) 2018-08-02
CN107602700A (zh) 2018-01-19
EP3875115A1 (en) 2021-09-08
US20180215814A1 (en) 2018-08-02
IL261927A (en) 2018-10-31
EA031065B1 (ru) 2018-11-30
SI3495392T1 (sl) 2021-11-30
HRP20210777T1 (hr) 2021-06-25
TR201904088T4 (tr) 2019-05-21
TWI692485B (zh) 2020-05-01
EP3495392B1 (en) 2021-08-18
JP6527563B2 (ja) 2019-06-05
US10066009B2 (en) 2018-09-04
CN108373502A (zh) 2018-08-07
PT3662932T (pt) 2021-05-14
HUE044062T2 (hu) 2019-09-30
IL270382B (en) 2020-11-30
CY1124515T1 (el) 2022-07-22
IL229431B (en) 2018-10-31
HUS2200031I1 (hu) 2022-07-28
HRP20211395T1 (hr) 2021-12-10
AU2017203890A1 (en) 2017-06-29
US9745373B2 (en) 2017-08-29
MX2019008185A (es) 2019-09-09
CA2836649C (en) 2020-06-23
CA3079978A1 (en) 2012-11-29
AR118605A2 (es) 2021-10-20
KR20140042819A (ko) 2014-04-07
AR086516A1 (es) 2013-12-18
ES2873837T3 (es) 2021-11-04
DK3495392T3 (da) 2021-09-13
PL3495392T3 (pl) 2021-12-13
EP2710039A4 (en) 2014-11-19
RS58621B1 (sr) 2019-05-31
AU2012258966C1 (en) 2022-02-03
RS62306B1 (sr) 2021-09-30
EP3662932A1 (en) 2020-06-10
IL261927B (en) 2019-11-28
US20190092842A1 (en) 2019-03-28
AP2013007259A0 (en) 2013-11-30
MX2019015745A (es) 2020-02-13
RS61793B1 (sr) 2021-06-30
AU2017203890B2 (en) 2019-06-06
US10208112B2 (en) 2019-02-19
HRP20190640T1 (hr) 2019-05-31
PE20180502A1 (es) 2018-03-09
JP6952736B2 (ja) 2021-10-20
NL301181I2 (nl) 2022-11-24
TW202033559A (zh) 2020-09-16
EP4115905A1 (en) 2023-01-11
CN107586338B (zh) 2021-09-17
KR102128627B1 (ko) 2020-06-30
PL3662932T3 (pl) 2021-09-06
IL268464A (en) 2019-09-26
SI2710039T1 (sl) 2019-05-31
HUE055505T2 (hu) 2021-11-29
US20210047391A1 (en) 2021-02-18
US10214582B2 (en) 2019-02-26
TWI685505B (zh) 2020-02-21
ZA201308637B (en) 2022-11-30
US20120294797A1 (en) 2012-11-22
CL2013003336A1 (es) 2014-06-06
DK3662932T3 (da) 2021-05-17
DK2710039T3 (en) 2019-04-01
LTPA2022511I1 (pt) 2022-07-11
EA201592042A1 (ru) 2016-03-31
JP6282584B2 (ja) 2018-02-21
PH12018500521A1 (en) 2019-04-15
LT3495392T (lt) 2021-09-27
US10189895B2 (en) 2019-01-29
CN108424452B (zh) 2021-08-03
LT2710039T (lt) 2019-04-25
EA201891284A1 (ru) 2018-11-30
EP2710039B1 (en) 2019-01-09
LT3662932T (lt) 2021-06-10
PL2710039T3 (pl) 2019-07-31
EP3662932B1 (en) 2021-04-07
US20190211085A1 (en) 2019-07-11
EA039905B1 (ru) 2022-03-25
US10179809B2 (en) 2019-01-15
SG10201604040PA (en) 2016-07-28
CY1124209T1 (el) 2022-05-27
CL2018001452A1 (es) 2018-08-10
NL301181I1 (pt) 2022-06-15
NZ618637A (en) 2016-03-31
HUE054437T2 (hu) 2021-09-28
CO6870005A2 (es) 2014-02-20
US11111289B2 (en) 2021-09-07
CA2836649A1 (en) 2012-11-29
CL2017001379A1 (es) 2017-12-29
ES2715001T3 (es) 2019-05-31
PT3495392T (pt) 2021-09-22
CA3080000A1 (en) 2012-11-29
TWI719869B (zh) 2021-02-21
US20170174754A1 (en) 2017-06-22
BR112013029932A2 (pt) 2017-01-31
WO2012162243A2 (en) 2012-11-29
ES2893073T3 (es) 2022-02-07
TWI646111B (zh) 2019-01-01
EP3495392A1 (en) 2019-06-12
MX370749B (es) 2019-12-20
FR22C1032I2 (fr) 2023-06-02
AU2019226231A1 (en) 2019-09-26
CN103748111A (zh) 2014-04-23
JP2018038391A (ja) 2018-03-15
PE20141787A1 (es) 2014-12-07
US20180215815A1 (en) 2018-08-02
AU2019226231B2 (en) 2021-06-03
FR22C1032I1 (fr) 2022-09-09
IL268464B (en) 2020-10-29
SG194938A1 (en) 2013-12-30
CN108424452A (zh) 2018-08-21
AR123876A2 (es) 2023-01-18
CN103748111B (zh) 2018-04-27
WO2012162243A3 (en) 2013-01-17
BR122022012930B1 (pt) 2023-10-10
CN108373502B (zh) 2022-03-22
AU2012258966B2 (en) 2017-03-09
TW201300419A (zh) 2013-01-01
TW201936642A (zh) 2019-09-16
CN107586338A (zh) 2018-01-16
JP2019150044A (ja) 2019-09-12
EP2710039A2 (en) 2014-03-26
SI3662932T1 (sl) 2021-08-31
TW201811835A (zh) 2018-04-01
US10533048B2 (en) 2020-01-14
US20180215816A1 (en) 2018-08-02
MX2013013535A (es) 2015-08-20
JP2014517699A (ja) 2014-07-24
NZ717570A (en) 2018-09-28

Similar Documents

Publication Publication Date Title
HUS2200031I1 (hu) Anti-CGRP készítmények és alkalmazásuk
EP2758183A4 (en) BIODEGRADABLE COMPOSITIONS AND THEIR USE
IL229844B (en) Anti-psgl-1 antibodies and their use
ZA201404399B (en) Bio-pesticide methods and compositions
PL2771071T3 (pl) Kompozycje perfumeryjne i ich zastosowanie
GB201113770D0 (en) Novel compositions and uses thereof
HK1191034A1 (en) N-carboxyalkyl-auristatins and use thereof n-
IL232362A0 (en) The chemical composition containing fluorine and its use
HUE041627T2 (hu) Tisztító készítmények és eljárások
EP2668044A4 (en) COMPOSITIONS AND THEIR USE
ZA201308892B (en) Compositions and methods
EP2766357A4 (en) MESOBILIVERDINE COMPOSITIONS AND METHOD THEREFOR
EP2686335A4 (en) DECORINAL COMPOSITIONS AND THEIR USE
GB201106357D0 (en) Composition and uses thereof
EP2693879A4 (en) MIGRASTATINES AND THEIR USES
HK1198587A1 (en) Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals -2-
GB201120470D0 (en) Compositions and uses thereof
GB201107454D0 (en) Compositions and uses
GB201101924D0 (en) Compositions and uses
GB201116340D0 (en) Compositions and methods
IL231477A0 (en) Degradable vehicles and their use